慢性乙型肝炎患者血清前S1抗原与血清HBV DNA和HBeAg的关系探讨

doi:10.3969/j.issn.1672-5069.2014.03.022

Abstract

B, Wen Zhengyan. Implication of serum Pre-S1 and its correlation to serum HBV DNA and HBeAg in patients with chronic hepatitis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 301-303.

[1] 郭继中,胡志刚,陈国千,等.前S1、HBV DNA、HBeAg反映乙型肝炎病毒复制的临床应用研究.胃肠病学和肝病学杂志,2008,17（11）：907-909.
[2] 滕春燕,刘爱中,王春娥,等. 前S1抗原与其他乙型肝炎病毒标志物的相关性及其临床意义.中国实验诊断学,2008,12（7）：894-896.
[3] 单万水,韩红星,杨燕,等. 乙型肝炎病毒DNA和前S1抗原及其标记物三者相关性分析. 中国热带医学,2006,6（1）：36-37.
[4] 王玉梅,张莲花,刘红春.乙型肝炎病毒前S1抗原的临床应用价值. 山东医药,2007,47（27）：48.
[5] Gous N,Bhimma R,Kew M,et al. Retrospective characterization of the S open reading frame of HBV isolated from children with membranous nephropathy treated with interferon-alpha2b. Antivir Ther,2010,15（1）:61-69.
[6] Huang X,Qin Y,Zhang P,et al. PreS deletion mutations of hepatitis B virus in chronically infected patients with simultaneous seropositivity for hepatitis-B surface antigen and anti-HBS antibodies. J Med Virol,2010,82（1）:23-31.
[7] Malik IR,Chen A,Brass A,et al. A bi-functional hepatitis B virus core antigen （HBcAg） chimera activates HBcAg-specific T cells and Pre S1-specific antibodies. Scand J Infect Dis,2012,44（1）:55-59.
[8] Chen H,Wen B,Deng Y,et al. Enhanced effect of DNA immunization plus in vivo electroporation with a combination of hepatitis B virus core-Pre S1and S-Pre S1plasmids. Clin Vaccine Immunol,2011,18（11）:1789-1795.
[9] Meier A,Mehrle S,Weiss TS,et al. Myristoylated Pre S1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatology,2013,58（1）31-42.
[10] Murata M,Narahara S,Umezaki K,et al. Liver cell specific targeting by the Pre S1 domain of hepatitis B virus surface antigen displayed on protein nanocages. Int J Nanomedicine,2012,7:4353-4362.
[11] Cai WJ,Yin L,Zhou D,et al. Association between polymorphisms of the E-selectin gene,hepatitis B virus DNA copies and Pre S1 antigen in patients with chronic hepatitis B infection. Mol Med Rep,2012,6（5）:1069-1074.
[12] Joob B,Wiwanitkit V. Time-resolved fluoroimmunoassay for hepatitis B virus Pre S1 antigen detection. J Immunoassay Immunochem,2012,33（3）:337.

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.

Implication of serum Pre-S1 and its correlation to serum HBV DNA and HBeAg in patients with chronic hepatitis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments